Nanodropper, a leader in micro-volume ophthalmic delivery, has announced that it will now operate under the name Mu Medical, following agreements with Bedo Solutions and Viseon Labs to join its precision eyecare platform. This strategic consolidation represents a major step forward, transitioning Nanodropper from a single-product device company into a full commercial-stage medtech ecosystem. Once finalized, the integration of Bedo Solutions and Viseon Labs’ assets and intellectual property with Nanodropper’s existing infrastructure will create a unified platform combining hardware and software solutions designed to address the complete lifecycle of ocular care.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
Dr. Allisa Song, Founder and CEO of Nanodropper, explained that traditional eyecare has often relied on a one-size-fits-all approach, from standardized drop sizes to static treatment plans. She emphasized that Mu Medical is being developed to deliver a more personalized experience. By incorporating Bedo Solutions and Viseon Labs into the platform, the company will be able to offer precise dosing, monitor patient adherence at home, and leverage AI analytics to adjust therapy in real time, improving both outcomes and patient engagement.
Health Technology Insights: Rocket Doctor AI Partners to Boost AI Clinical Support in Alberta
The merger brings together three physician-led companies, each founded with a focus on patient-centered care and practical innovation. This shared clinical perspective ensures that the combined technologies are designed to make meaningful therapeutic impacts and improve access to advanced eyecare solutions. Following the consolidation, the leadership team at Mu Medical will include Dr. Allisa Song as CEO and Board Chair, Dr. Sina Fateh, Founder and CEO of Viseon Labs, as Chief Strategy Officer and Board Observer, and Dr. Robert Kinast, Founder and CEO of Bedo Solutions, as Board Observer and Medical Advisor.
Mu Medical’s portfolio will be organized into four integrated verticals. The Consumer Devices division includes Nanodropper Adaptor and GentleDrop, designed to optimize daily therapy. The Primary Packaging vertical features MuPACK-JT2, MuVEYE, and MuMIST, enabling precise dosing at the source. The Monitoring and Oculomics division uses VuTRACK, which applies machine vision to track adherence and generate actionable health insights. The AI Therapeutics vertical includes Myopia AI and VizGuard, leveraging advanced analytics to guide personalized treatment decisions. Together, these four areas provide a comprehensive approach to modern eyecare, from therapy delivery to data-driven treatment planning.
Dr. Allisa Song and Dr. Sina Fateh will officially introduce Mu Medical during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to 15, 2026. In addition, Viseon Labs has been selected as a featured presenter at the MIT Innovation Showcase and Reception, where the leadership team will share the Mu Medical vision with investors and the medtech community. This expansion positions Mu Medical as a pioneering force in personalized and technology-driven eyecare, aiming to redefine how therapies are delivered, monitored, and optimized for every patient.
Health Technology Insights: Amphista Reveals AMX-883 Preclinical Data for AML Therapy
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
